Tuesday, March 29, 2011
Since its foundation in 1997, MagForce Nanotechnologies’ vision has been to apply advanced nanomedicine for therapy innovation. Now, as the first company worldwide to receive European approval for a medical product using nanoparticles, the company’s NanoTherm® therapy is a novel method for the treatment of solid tumors. Well tolerated by patients, the specific focus of heat within the tumor spares the surrounding healthy tissue. NanoTherm® therapy has, therefore, the potential to establish itself, along with surgery, radiotherapy, and chemotherapy, as an additional pillar of cancer treatment.
The principle of the NanoTherm® treatment is the use of nanoparticles containing ironoxide, which are injected into solid tumors in a procedure similar to a biopsy. The patient is then placed in a magnetic field applicator (Nano-ActivatorTM), a machine that produces an alternating magnetic field. Through this high frequency magnetic field, the nanoparticles begin to oscillate and warmth is produced from directly within the tumor tissue. Depending on the temperature reached and the length of treatment, the tumor cells are either destroyed or sensitized for the accompanying chemotherapy or radiation.
MagForce is currently preparing the NanoTherm® European product launch. In Germany, patient treatment will soon be introduced at the Charité Universitätsmedizin in Berlin. For more information on this innovative cancer therapy, please click here